Compare DRIO & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | ZTEK |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 89.3M |
| IPO Year | N/A | N/A |
| Metric | DRIO | ZTEK |
|---|---|---|
| Price | $11.42 | $0.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | 29.3K | ★ 47.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,732,000.00 | $657,134.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.29 | ★ 2225.73 |
| 52 Week Low | $5.94 | $0.62 |
| 52 Week High | $31.00 | $1.84 |
| Indicator | DRIO | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 51.65 |
| Support Level | $11.93 | $0.64 |
| Resistance Level | $12.88 | $0.75 |
| Average True Range (ATR) | 0.74 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 14.75 | 69.46 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.